Clinical and fiscal impact of lansoprazole intolerance in veterans with gastro-oesophageal reflux disease

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 4, 2000, Pages 397-406

  Gerson, L B ^a,b,d   Hatton, B N ^c   Ryono, R ^d   Jones, W ^e   Pulliam, G ^c   Sampliner, R E ^c   Triadafilopoulos, G ^a   Fass, R ^c  

^a S U S of M/VA P A H C S ^*  (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^e SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ABDOMINAL PAIN; ARTICLE; DATA BASE; DIARRHEA; DRUG COST; DRUG FORMULARY; DRUG HYPERSENSITIVITY; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; PRIORITY JOURNAL; RASH; SOLDIER;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AGED; COSTS AND COST ANALYSIS; ENZYME INHIBITORS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMPS;

EID: 0034038897     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00726.x     Document Type: Article

References (25)

1. 1 Medical Advisory Panel for Pharmacy Benefits Management Strategic Health Group. Department of Veteran Affairs. Contract Adherence Reports. Quarter 3, Fiscal Year, 1998.
2. 2 Hatton BN, Gerson L, Jones W, et al. Assessment of patients at a VA Medical Center treated with omeprazole due to lansoprazole intolerance. Gastroenterology 1999; 116(Part II): G0797.
3. 3 Locke G, Talley N, Zinsmeister A. A new questionnaire for gastroesophageal reflux disease. Mayo Clinic Proc 1994; 69: 539-47.
4. 4 Seensalu R, Iwarzon M, Janczewska I, et al. Dose-response comparison of lansoprazole and omeprazole on 24-hour gastric acidity and plasma gastrin in healthy volunteers. Gastroenterology 1995; 108: A215(Abstract).
5. 5 Dammann HG, Fuchs W, Richter G, Burkhardt F, Wolf N, Walter TA. Lansoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion. Aliment Pharmacol Ther 1997; 11: 359-64.
6. 6 Castell DO, Richter JE, Robinson M, et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. Am J Gastroenterol 1996; 91: 1749-57.
7. 7 Blum RA, Shi H, Karol M, et al. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. Clin Therapeutics 1997; 5: 1013-23.
8. 8 Tolman KG, Sanders SW, Buchi KN, Karol MD, Jennings DE, Ringham GL. The effects of oral doses of lansoprazole and omeprazole on gastric pH. J Clin Gastroenterol 1997; 24: 65-70.
9. 9 Bruley Des Varannes S, Levy P, Lartigue S, Dellatolas F, Lemaire M, Galmiche JP. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers. Aliment Pharmacol Ther 1994; 8: 309-14.
10. 10 Hatlebakk JG, Berstad A, Carling L, et al. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a scandinavian multicentre trial. Scand J Gastroenterol 1993; 28: 224-8.
11. 11 Mee AS, Rowley JL and the Lansoprazole Clinical Research Group. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. Aliment Pharmacol Ther 1996; 10: 757-63.
12. 12 Mulder CJ, Dekker W, Gerretsen M, et al. Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II III and IVa (a Dutch multicentre trial). Dutch Study Group. Eur J Gastroenterol Hepatol 1996; 8: 1101-6.
13. 13 Timmer W, Ripke H, Kleist P, et al. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects. Meth Find Exp Clin Pharmacol 1995; 17: 489-95.
14. 14 Schaberg JW, Chockalingam SK, Mahmoud MA, et al. The impact of formulary change in proton pump inhibitor (PPI) as maintenance treatment for gastroesophageal reflux disease (GERD). Gastroenterology 1999; 116: G0400.
15. 15 Janczewska I, Sagar M, Sjostedt S, Hammarlund B, Iwarzon M, Seensalu R. Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease. Scand J Gastroenterol 1998; 33: 1239-43.
16. 16 Ouatu-Lascar R, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1998; 93: 711-6.
17. 17 Krinsky ML, Alexis G, Hirano I. Chronic diarrhea from lansoprazole use in the veteran population. Gastroenterology 1999; 116(Part II): G0976.
18. 18 Thomson RD, Bensen SP, Toor A, Maheshwari Y. Lansoprazole associated microscopic colitis. Gastroenterology 1999; 116(Part II): G4084.
19. 19 Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997; 92: 1997-2000.
20. 20 Fass R, Fennerty MB, Yalam JM, et al. Evaluation of the 'omeprazole test' in patients with typical symptoms of gastroesophageal reflux disease (GERD). Gastroenterology 1997; 112: A114(Abstract).
21. 21 Johnsson F, Weywadt L, Solhaug JH, Hernqvist H, Bengtsson L. One-week omeprazole treatment in the diagnosis of gastrooesophageal reflux disease. Scand J Gastroenterol 1998; 33: 15-20.
22. 22 Bukstein DA. Incorporating quality of life data into managed care formulary decisions: a case study with salmeterol. Am J Managed Care 1997; 3: 1701-6.
23. 23 Horn SD, Sharkey PD, Phillips-Harris C. Formulary limitations and the elderly: results from the Managed Care Outcomes Project. Am J Managed Care 1998; 4: 1105-13.
24. 24 Condra LJ, Morreale AP, Stolley SN, et al. Assessment of patient satisfaction with a formulary switch from omeprazole to lansoprazole in gastroesophageal reflux disease maintenance therapy. Am J Managed Care 1999; 5: 631-8.
25. 25 Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996; 11: 85-92.